國家衛生研究院 NHRI:Item 3990099045/3821

NHRI > Institute of Molecular and Genomic Medicine > Lu-Hai Wang > Conference Papers/Meeting Abstract > Item 3990099045/3821

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/3821

Title:	Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells
Authors:	Schlosshauer, PW;Li, W;Lin, KT;Chan, JLK;Wang, LH
Contributors:	Division of Molecular and Genomic Medicine
Abstract:	Objective: The current standard treatment for ovarian carcinoma, consisting of surgery followed by chemotherapy with carboplatin and paclitaxel, is fraught with a high rate of recurrences. We hypothesized that targeted inhibition of specific signaling pathways in combination with conventional drugs may increase chemotherapeutic efficacy. Methods: We analyzed the expression and activation profiles of various signaling pathways in nine established ovarian cancer cell lines (CAOV-3, ES2, PA-1, SKOV-3, NIHOVCAR3, OV90, TOV112D, A1847, A2780) and 24 freshly procured human ovarian tumors. The PI3 kinase pathway component Akt was frequently overexpressed and/or activated in tumor cells. The effect of several PI3K pathway inhibitors (rapamycin, LY294002, SH-6) and rapamycin in combination with carboplatin on various tumor cell growth characteristics was tested in cell lines and fresh tumor-derived transient monolayer and organ cultures. Results: Rapamycin by itself and additively with carboplatin inhibited the growth and invasion, and increased the sensitivity to anoikis of most of the ovarian cancer cell lines and fresh tumors. The additive inhibitory effect may be due to enhanced apoptosis as demonstrated by Poly-ADP-Ribose Polymerase (PARP) cleavage and Annexin V staining in cells treated with both rapamycin and carboplatin. Conclusions: Rapamycin in combination with standard chemotherapeutic agents may improve the efficiency of ovarian cancer treatment.
Date:	2009-09
Relation:	Gynecologic Oncology. 2009 Sep;114(3):516-522.
Link to:	http://dx.doi.org/10.1016/j.ygyno.2009.06.002
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0090-8258&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000269139800027
Cited Times(Scopus):	http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=67749123955
Appears in Collections:	[Lu-Hai Wang] Conference Papers/Meeting Abstract

Files in This Item:

File	Description	Size	Format
SCP67749123955.pdf		997Kb	Adobe PDF	1100	View/Open

Loading...